Infliximab biosimilar (Amgen) | m-entrepreneurship.com

Product Name :
Infliximab biosimilar (Amgen)

Search keywords :
Infliximab

drugId :
null

Target Vo:
Tumor necrosis factor α

Target Vo Short Name :
TNFα

Moa_Name:
Tumor necrosis factor α inhibitors

First Approval Country :
United States

First Approval Date Filter:
2019

Origin Company_Name :
Amgen Inc

Active Company_Name :
Amgen Inc

Active Indication_Name:
Plaque psoriasis

In Active Indication_Name:

Termination Status :

China Termination Status :

Highest Status:
Approved

China Highest Status:

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
HDAC2 Antibody (YA742)
Cyclin B1 Antibody (YA486)
GSDMD Antibody: GSDMD Antibody is an unconjugated, approximately 53 kDa, rabbit-derived, anti-GSDMD polyclonal antibody. GSDMD Antibody can be used for: WB, ELISA, IHC-P, IHC-F, ICC, IF expriments in human, and predicted: mouse, rat background without labeling.

Author: Betaine hydrochloride

Related Posts